Rxsight Inc
NASDAQ:RXST

Watchlist Manager
Rxsight Inc Logo
Rxsight Inc
NASDAQ:RXST
Watchlist
Price: 34.32 USD 1.84%
Market Cap: 1.4B USD
Have any thoughts about
Rxsight Inc?
Write Note

Rxsight Inc
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Rxsight Inc
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
Rxsight Inc
NASDAQ:RXST
Total Liabilities & Equity
$182.6m
CAGR 3-Years
22%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Haemonetics Corp
NYSE:HAE
Total Liabilities & Equity
$2.5B
CAGR 3-Years
12%
CAGR 5-Years
16%
CAGR 10-Years
6%
ICU Medical Inc
NASDAQ:ICUI
Total Liabilities & Equity
$4.3B
CAGR 3-Years
33%
CAGR 5-Years
21%
CAGR 10-Years
23%
Align Technology Inc
NASDAQ:ALGN
Total Liabilities & Equity
$6.4B
CAGR 3-Years
4%
CAGR 5-Years
22%
CAGR 10-Years
21%
Lantheus Holdings Inc
NASDAQ:LNTH
Total Liabilities & Equity
$2B
CAGR 3-Years
34%
CAGR 5-Years
38%
CAGR 10-Years
23%
Merit Medical Systems Inc
NASDAQ:MMSI
Total Liabilities & Equity
$2.4B
CAGR 3-Years
13%
CAGR 5-Years
6%
CAGR 10-Years
12%
No Stocks Found

Rxsight Inc
Glance View

Market Cap
1.4B USD
Industry
Health Care

In the dynamic realm of ophthalmology, RxSight Inc. has carved a niche as a pioneering force in enhancing vision outcomes for cataract patients. At the heart of the company’s innovation is its Light Adjustable Lens (LAL) system. Traditional intraocular lenses (IOLs), once implanted, lock patients into a certain prescription, accepting only minimal adjustments. RxSight, with its groundbreaking technology, offers a solution that breaks this convention. Post-cataract surgery, the LAL allows ophthalmologists to precisely adjust the lens prescription using UV light, often yielding better visual acuity tailored to patient needs. This transformative approach turns the one-size-fits-all model of vision correction into a personalized patient experience, promising a brighter, clearer outlook on life. Commercially, RxSight operates within the medical device industry, focusing on capturing a significant share of the cataract surgery market—one of the most frequent surgeries performed worldwide. The company earns revenue primarily through the sale of its LAL system to eye care professionals and clinics. This business model is akin to a razor-and-blade approach; besides the initial sale of the adjustable lenses, RxSight garners continuous revenue from associated products and services, such as the light delivery device and follow-up adjustments required post-surgery. By addressing a substantial unmet need with a recurring revenue stream, RxSight strategically positions itself for growth within the burgeoning biotech sector, all while setting new benchmarks for patient satisfaction in eye care.

RXST Intrinsic Value
14.51 USD
Overvaluation 58%
Intrinsic Value
Price

See Also

What is Rxsight Inc's Total Liabilities & Equity?
Total Liabilities & Equity
182.6m USD

Based on the financial report for Dec 31, 2023, Rxsight Inc's Total Liabilities & Equity amounts to 182.6m USD.

What is Rxsight Inc's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 3Y
22%

Over the last year, the Total Liabilities & Equity growth was 22%. The average annual Total Liabilities & Equity growth rates for Rxsight Inc have been 22% over the past three years .

Back to Top